4D Pharma PLC - ESG Rating & Company Profile powered by AI
If you are employed by 4D Pharma PLC and you would like to use your ESG aseessment, please get in touch. The webpage contains a free ESG assessment for 4D Pharma PLC. The webpage of 4D Pharma PLC is assembled by All Street Sevva using leading machine learning.
4D Pharma PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.6; made up of an environmental score of 2.7, social score of 3.2 and governance score of 2.0.
2.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1437 | Valenta Farmatsevtika AO | 2.7 | Medium |
| 1437 | Wockhardt Bio AG | 2.7 | Medium |
| 1481 | 4D Pharma PLC | 2.6 | Medium |
| 1481 | CTI Biopharma Corp | 2.6 | Medium |
| 1481 | Cannara Biotech Inc | 2.6 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does 4D Pharma PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes 4D Pharma PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes 4D Pharma PLC report the average age of the workforce?
Sign up for free to unlockDoes 4D Pharma PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes 4D Pharma PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes 4D Pharma PLC disclose cybersecurity risks?
Sign up for free to unlockDoes 4D Pharma PLC offer flexible work?
Sign up for free to unlockDoes 4D Pharma PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes 4D Pharma PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes 4D Pharma PLC conduct supply chain audits?
Sign up for free to unlockDoes 4D Pharma PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes 4D Pharma PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes 4D Pharma PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes 4D Pharma PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes 4D Pharma PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes 4D Pharma PLC disclose water use targets?
Sign up for free to unlockDoes 4D Pharma PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid 4D Pharma PLC have a product recall in the last two years?
Sign up for free to unlockDoes 4D Pharma PLC disclose incidents of discrimination?
Sign up for free to unlockDoes 4D Pharma PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas 4D Pharma PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes 4D Pharma PLC disclose parental leave metrics?
Sign up for free to unlockDoes 4D Pharma PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes 4D Pharma PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes 4D Pharma PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes 4D Pharma PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes 4D Pharma PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes 4D Pharma PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs 4D Pharma PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes 4D Pharma PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes 4D Pharma PLC disclose its waste policy?
Sign up for free to unlockDoes 4D Pharma PLC report according to TCFD requirements?
Sign up for free to unlockDoes 4D Pharma PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes 4D Pharma PLC disclose energy use targets?
Sign up for free to unlockDoes 4D Pharma PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes 4D Pharma PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for 4D Pharma PLC
These potential risks are based on the size, segment and geographies of the company.
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.